<SEC-DOCUMENT>0001193125-21-343190.txt : 20211130
<SEC-HEADER>0001193125-21-343190.hdr.sgml : 20211130
<ACCEPTANCE-DATETIME>20211130105859
ACCESSION NUMBER:		0001193125-21-343190
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20211130
FILED AS OF DATE:		20211130
DATE AS OF CHANGE:		20211130

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CYBIN INC.
		CENTRAL INDEX KEY:			0001833141
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A6
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40673
		FILM NUMBER:		211458647

	BUSINESS ADDRESS:	
		STREET 1:		100 KING STREET WEST
		STREET 2:		SUITE 5600
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5X 1C9
		BUSINESS PHONE:		(908) 764-8385

	MAIL ADDRESS:	
		STREET 1:		100 KING STREET WEST
		STREET 2:		SUITE 5600
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5X 1C9
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d234389d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR
<FONT STYLE="white-space:nowrap">15d-16</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of November, 2021. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number: <FONT STYLE="white-space:nowrap">001-40673</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Cybin Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name
of Registrant as Specified in Charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>100 King
Street West, Suite 5600, Toronto, Ontario, M5X 1C9 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT
STYLE="white-space:nowrap">40-F.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
<FONT STYLE="white-space:nowrap">20-F&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT> Form <FONT STYLE="white-space:nowrap">40-F&nbsp;&nbsp;&#9746;</FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule
101(b)(1) only permits the submission in paper of a Form <FONT STYLE="white-space:nowrap">6-K</FONT> if submitted solely to provide an attached annual report to security holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule
101(b)(7) only permits the submission in paper of a Form <FONT STYLE="white-space:nowrap">6-K</FONT> if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the
jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home country exchange on which the registrant&#146;s securities are traded, as long as
the report or other document is not a press release, is not required to be and has not been distributed to the registrant&#146;s security holders, and, if discussing a material event, has already been the subject of a Form <FONT
STYLE="white-space:nowrap">6-K</FONT> submission or other Commission filing on EDGAR. </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CYBIN INC.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Registrant)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: November&nbsp;30, 2021</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><I>/s/ Doug Drysdale</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Doug Drysdale</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT INDEX </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d234389dex991.htm">News Release dated November&nbsp;29, 2021 </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d234389dex992.htm">News Release dated November&nbsp;30, 2021 </A></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d234389dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g234389g1130091552636.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Cybin to Participate in the H.C. Wainwright 2<SUP STYLE="font-size:85%; vertical-align:top">nd</SUP>
Annual Psychedelics Conference on December&nbsp;6, 2021 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>TORONTO, CANADA </B>&#150; November&nbsp;29, 2021 &#150; <U>Cybin</U><U> Inc.</U>
(<U>NEO:CYBN</U>) (<U>NYSE American:CYBN</U>) (&#147;<B>Cybin</B>&#148; or the &#147;<B>Company</B>&#148;), a biopharmaceutical company focused on progressing &#147;Psychedelics to
Therapeutics<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP>&#148; is pleased to announce that Doug Drysdale, Cybin&#146;s Chief Executive Officer, will participate in a fireside chat at the
2<SUP STYLE="font-size:85%; vertical-align:top">nd</SUP> Annual H.C. Wainwright Psychedelics Conference being held virtually on Monday, December&nbsp;6, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Drysdale&#146;s fireside chat will be available on demand beginning on December&nbsp;6, 2021 at 7:00 a.m. ET. To listen to the event, please click
here to access the webcast. The archived webcast will also be available on the Company&#146;s investor relations website on the Events<U></U>&nbsp;&amp; Presentations page. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Cybin </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cybin is a leading ethical biopharmaceutical
company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and
founded in 2019, Cybin is operational in the United States, United Kingdom and Ireland. The Company is focused on progressing Psychedelics to Therapeutics<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> by engineering proprietary drug
discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor&nbsp;&amp; Media Contacts:</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Leah Gibson </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vice President, Investor Relations </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cybin Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>leah@cybin.com </U></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>d234389dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g234389g1130091656265.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Cybin Announces FDA Investigational New Drug and Institutional </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Review Board Approvals for a <FONT STYLE="white-space:nowrap">Co-Funded</FONT> Phase 2 Clinical Trial to </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Treat Frontline Clinicians Experiencing COVID-Related Distress </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>- Trial to be conducted at University of Washington, led by Dr.&nbsp;Anthony Back - </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>TORONTO, CANADA </B>&#150; November&nbsp;30, 2021 &#150; <U>Cybin</U><U> Inc.</U> (<U>NEO:CYBN</U>) (<U>NYSE American:CYBN</U>) (&#147;<B>Cybin</B>&#148;
or the &#147;<B>Company</B>&#148;), a biopharmaceutical company focused on progressing &#147;Psychedelics to Therapeutics<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP>&#148;, today announced that the U.S. Food and Drug Administration
(&#147;FDA&#148;) has authorized an investigator-initiated randomized, placebo-controlled Phase 2 clinical trial evaluating psychedelic-assisted psychotherapy with psilocybin for frontline clinicians experiencing COVID-related distress. The trial
will be conducted at the University of Washington and will aim to treat symptoms of depression, anxiety, burnout and post-traumatic stress among frontline doctors, nurses and healthcare professionals. The trial&#146;s Primary Investigator,
Dr.&nbsp;Anthony Back, received an investigational new drug (&#147;IND&#148;) approval letter from the FDA, which provides authority to proceed with the Phase 2 trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further to the authorization from the FDA, the study has also received Institutional Review Board (&#147;IRB&#148;) approval at the University of Washington.
This investigator-initiated trial will be hosted in Seattle, a city significantly impacted by the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and will be funded by multiple organizations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;This study offers an important opportunity to assess psychedelics-assisted therapy as a new modality for clinicians who have suffered as a result of
their frontline work in the pandemic,&#148; said Dr.&nbsp;Anthony Back. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To support the initiative, Cybin&#146;s Chief Clinical Officer, Alex Belser, PhD
and Bill Brennan, PhD (candidate) developed EMBARK, a <FONT STYLE="white-space:nowrap">six-domain</FONT> model of psychedelic-assisted psychotherapy. EMBARK was designed as a transdiagnostic psychotherapy model that can be adapted to address a range
of clinical indications and populations. In collaboration with Dr.&nbsp;Anthony Back and Ladybird Morgan, RN, MSW, an adapted version of EMBARK has been <FONT STYLE="white-space:nowrap">co-authored</FONT> to treat COVID-related burnout and symptoms
of depression among frontline healthcare workers, and this version includes material that specifically addresses cultural inclusion anticipating a diverse population of clinicians.<U> Cybin launched the EMBARK Psychedelic Facilitator Training
Program</U> for study facilitators in October 2021. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Throughout the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, nurses, doctors, and
healthcare professionals on the frontlines have worked hard to provide care under extremely difficult circumstances. Understandably, under this stress, many frontline healthcare workers have experienced symptoms of depression and burnout. We believe
psychedelic medicine, when given with a supportive psychotherapy program like the EMBARK approach, may provide a promising treatment approach to bolster mental health,&#148; said Dr.&nbsp;Alex Belser, Cybin&#146;s Chief Clinical Officer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;This clinical trial provides an opportunity to better understand the effectiveness of combining psilocybin and EMBARK. Learnings from this combination
Phase 2 trial will inform the use of EMBARK in Cybin&#146;s upcoming human studies using CYB003, a proprietary deuterated psilocybin analog that has the potential to reduce clinic times and dosing levels in half as well as potentially reduce side
effects and adverse events,&#148; said Doug Drysdale, Chief Executive Officer of Cybin. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About the Phase 2 trial </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Phase 2 clinical trial will enroll 30 frontline clinicians (physicians, nurse practitioners, physician assistants, nurses). Inclusion criteria include
clinically significant symptoms of depression and anxiety (primary outcome) and existential distress (secondary outcome) following work exposure during the COVID pandemic. The trial will employ a randomized parallel design methodology using an
active placebo. The primary outcome will be a comparison between the two groups in depression and anxiety as measured by the Montgomery Asberg Depression Rating Scale (MADRS) total at 4 weeks post dose session. The secondary outcome will be a
comparison between the two groups in symptoms of existential distress measured by the Demoralization <FONT STYLE="white-space:nowrap">DS-ii</FONT> at 4 weeks post dose session. A mediation analysis of self-reported mystical states (Mystical
Experience <FONT STYLE="white-space:nowrap">Questionnaire-30</FONT> item <FONT STYLE="white-space:nowrap">(MEQ-30))</FONT> and psychological flexibility (Acceptance and Action Questionnaire II (AAQII)) on changes in the primary outcome (HADS) will
be analyzed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additional assessments include measures of clinician burnout (Stanford Fulfillment Index), post-traumatic stress (PTSD Checklist for <FONT
STYLE="white-space:nowrap">DSM-5</FONT> <FONT STYLE="white-space:nowrap">(PCL-5))</FONT> and a semi-structured interview to identify factors that positively and negatively influence the integration phase of psychedelic-assisted psychotherapy. The
assessment will also characterize the process of psychological change and effects on work and home life. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Anthony Back is a recognized leader in
the fields of palliative care and oncology. He is a board-certified physician at the University of Washington, Founding <FONT STYLE="white-space:nowrap">Co-director</FONT> of the University of Washington Center for Excellence in Palliative Care, and
a University of Washington professor of Oncology and Medicine. He is triple board certified in Hospice and Palliative Medicine, Medical Oncology and General Internal Medicine. He was the principal investigator for the National Cancer
Institute-funded Oncotalk interventions, which enabled the founding of the nonprofit VitalTalk, <FONT STYLE="white-space:nowrap">co-wrote</FONT> <I>Mastering Communication with Seriously Ill Patients</I>, produced the first iPhone app for clinician
communication skills, and is a Contemplative Studies Fellow of the Mind and Life Institute. His clinical and research interests include patient-physician communication and quality of life in palliative care. Dr.&nbsp;Back earned his medical degree
at Harvard Medical School. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Cybin </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to
create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in the USA, UK and Ireland. The Company is focused on progressing Psychedelics to
Therapeutics<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cautionary Notes and Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain
statements in this press release constitute forward-looking information. All statements other than statements of historical fact contained in this press release, including, without limitation, statements regarding Cybin&#146;s future, strategy,
plans, objectives, goals and targets, and any statements preceded by, followed by or that include the words &#147;believe&#148;, &#147;expect&#148;, &#147;aim&#148;, &#147;intend&#148;, &#147;plan&#148;, &#147;continue&#148;, &#147;will&#148;,
&#147;may&#148;, &#147;would&#148;, &#147;anticipate&#148;, &#147;estimate&#148;, &#147;forecast&#148;, &#147;predict&#148;, &#147;project&#148;, &#147;seek&#148;, &#147;should&#148; or similar expressions or the negative thereof, are
forward-looking statements. Forward-looking statements in this news release include statements regarding the Company&#146;s proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens
to potentially treat psychiatric disorders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These forward-looking statements are based on reasonable assumptions and estimates of management of the
Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or
achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: implications of the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic on the Company&#146;s operations; fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of
the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company
operates; and the risk factors set out in the Company&#146;s management&#146;s discussion and analysis for the period ended September&nbsp;30, 2021 and the Company&#146;s listing statement dated November&nbsp;9, 2020, which are available under the
Company&#146;s profile on www.sedar.com and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or
believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated,
estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions,
projections, or other factors, should they change, except as required by law. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cybin makes no medical, treatment or health benefit claims about Cybin&#146;s proposed products. The U.S.
Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not
been confirmed by approved research. There is no assurance that the use of psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific
research and clinical trials are needed. Cybin has not conducted clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy and safety of potential products do not imply that Cybin verified such in
clinical trials or that Cybin will complete such trials. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin&#146;s performance and operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Neither the Neo Exchange Inc. nor the NYSE American LLC stock exchange have approved or disapproved the contents of this news release and are not
responsible for the adequacy and accuracy of the contents herein. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor&nbsp;&amp; Media Contact: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Leah Gibson </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vice President, Investor Relations </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cybin Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>leah@cybin.com </U></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g234389g1130091552636.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g234389g1130091552636.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #2 2,# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MYQ@Y)KTBKJTI4Y<LMQ)IJZ"BBBLQA1110 4444 %%%% !1110 4444 %%%%
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M'GUGPK]KMT+7.GMYP ZE,?,/RY_"OGP'H0?<&O=P<U.BEVT.:HK2/L"BN?\
M!>OP>(O#%G=QR*TRH(YUSRK@8.?KU_&N@KQ)1<9.+Z'0G=7"BHKFY@L[=Y[F
M:.&%!EGD8* /J:\D\8_%Y2LECX:Y)^5KYEX'^X#U^IJZ5"=5VBA2DH[G6>-_
MB%8^%(&MH=MSJCK\D /"?[3^@]N]<)\-;GQ#XD\;R:K<W]R]O"I,^7/EG/1
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
' %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g234389g1130091656265.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g234389g1130091656265.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #2 2,# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HK(UWQ/H_AR#S=4OHX21E8^KO]%')KSG4OCA&KE=*T
M9Y%'22YEVY_X",_SK:GAZM36*)<XK<]=HKQFP^.%R)P-1T:(PD\M;2G</P;K
M^8KU31-=T[Q#IR7VFSB6%N".C(?1AV-%7#U*6LD$9J6QI4445B4%%%% !111
M0 4453U74H-(TNYU"Y8+% A=O?VII-NR Y?Q[X]A\(VJ06Z)/J4PS'&Q^5!_
M>;_"E^&_B;4?%&@S76I+%YT<Q0-&FT,/I7@6M:M<Z_K-QJ-P2TL[_*OH.RBO
MHSP)HG]@>$;*T88F9?,E_P!YN:]#$4(4:"3^)F4).4O(Z2BBBO.-0HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\N\=_%--,DDTO
M0&26\7Y9;D\I$?0>K?H*B^*/C]K$/H&D38NF&+J=#S$#_"/]H_H*\5KT\)@U
M)>TJ?)&-2I;1$MU=7%]=27-W/)//(<O)(V6-;OAWP/KWB=?,T^T"VP.#<3ML
M3\.Y_ 5O?#OX>OXEF74M25DTJ-OE7H9R.P_V?4U[Y!!%;0)!!&L<4:A41!@*
M/05MB<8J3Y(;DPIWU9\W>)?AYKOA:S%Y=K!/:Y :6W8D(3TR" ?QH^'_ (HE
M\,^)(69S]BN6$5PG;!Z-]17N_C6*.;P7JZR %?LSGGUQ7RX#\H/<<U>&J/$T
MFIBFN26A]@ @@$'(/0TM9'A:Y>[\*Z7/(<N]LF3^&*UZ\22LVCI04444@"BB
MB@ KR+XT>(2D5MH,#\O^^GQZ?PBO6II4@A>60X1%+,?0"OE?Q-K#Z[XBOM1<
MY$DAV>RC@5W8"ESU.9]#*K*RL;'PXT#^WO%UN)$S;6O[^7TXZ#\Z^D^@XKS_
M .$N@?V5X6%]*F+B^/F'(Y"?PBO0*C&U?:5;+9#IQM$***Q/%NO_ /"->&[K
M5%B$KQ@!$)P"QZ9]JY8Q<FHKJ:-V-NBO-_ASX_U3Q7J=Y::A;VRB.,2(\"D8
MYQ@Y)KTBKJTI4Y<LMQ)IJZ"BBBLQA1110 4444 %%%% !1110 4444 %%%%
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M'GUGPK]KMT+7.GMYP ZE,?,/RY_"OGP'H0?<&O=P<U.BEVT.:HK2/L"BN?\
M!>OP>(O#%G=QR*TRH(YUSRK@8.?KU_&N@KQ)1<9.+Z'0G=7"BHKFY@L[=Y[F
M:.&%!EGD8* /J:\D\8_%Y2LECX:Y)^5KYEX'^X#U^IJZ5"=5VBA2DH[G6>-_
MB%8^%(&MH=MSJCK\D /"?[3^@]N]<)\-;GQ#XD\;R:K<W]R]O"I,^7/EG/1
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
' %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
